© 2004 European Society for Medical Oncology
Original Article |
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia
Waldenstrom's Macroglobulinemia Program, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02116, USA
* Correspondence to: Dr S. P. Treon, Dana Farber Cancer Institute, LG102, 44 Binney Street, Boston, MA 02115, USA. Tel: +1-617-632-2681; Fax: +1-617-632-4862; Email: steven_treon{at}dfci.harvard.edu
Background: The anti-CD20 monoclonal antibody rituximab is an important therapeutic in Waldenstrom's macroglobulinemia (WM), producing response rates of 50–70%. Responses, which are based on serum IgM levels, have typically been evaluated at 12 weeks. Paradoxically, we have observed that serum IgM levels can abruptly rise following rituximab therapy in patients with WM, and can often lead to morbidity on the basis of hyperviscosity.
Patients and methods: Eleven WM patients with CD20+ tumor cells who received rituximab at our Institution and had serum IgM levels measured within a 12-week period following start of therapy were evaluated. Therapy consisted of four weekly infusions of rituximab at 375 mg/m2. Pre- and post-therapy serum IgM levels were determined by nephelometry and corresponding serum viscosity levels were determined by viscometry.
Results: Ten of the 11 patients demonstrated an abrupt rise in serum IgM levels, with a >25% increase occurring in eight (73%) patients. Mean serum IgM levels for all 10 spiking patients rose from 4370 (range, 655–7940) to a peak of 5865 (range, 872–11 800) mg/dl (P=0.004), which occurred at a mean of 4 (range, 1–8) weeks following initiation of therapy. Mean serum viscosity levels also increased from 3.5 to 5.6 centipoise (CP) (P=0.09) in eight patients for whom pre- and post-therapy studies were obtained. A subdural hemorrhage occurred in one patient when serum IgM levels rose from 7530 to 11 800 mg/dl, and serum viscosity increased from 3.9 to 10.1 CP. Two other spiking patients with pre-therapy IgM levels of >5000 mg/dl experienced worsening headaches and/or epistaxis attributed to increasing serum viscosity.
Conclusions: Abrupt increases in serum IgM levels commonly occur following rituximab therapy in WM. Careful clinical and laboratory monitoring is warranted, particularly if patients have pre-therapy serum IgM levels of >5000 mg/dl. The mechanism of this effect is under active investigation, and may be related to CD20 signaling triggered by rituximab.
Key words: hyperviscosity, Rituximab, serum IgM, Waldenstrom's macroglobulinemia
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. P. Treon, A. R. Branagan, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, B. Turnbull, P. Wasi, C. Emmanouilides, S. R. Frankel, A. Lister, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia Blood, April 16, 2009; 113(16): 3673 - 3678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Treon, J. D. Soumerai, A. R. Branagan, Z. R. Hunter, C. J. Patterson, L. Ioakimidis, L. Chu, P. Musto, A. D. Baron, J. C. Nunnink, et al. Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia Clin. Cancer Res., January 1, 2009; 15(1): 355 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Treon, J. D. Soumerai, A. R. Branagan, Z. R. Hunter, C. J. Patterson, L. Ioakimidis, F. M. Briccetti, M. Pasmantier, H. Zimbler, R. B. Cooper, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia Blood, December 1, 2008; 112(12): 4452 - 4457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Dimopoulos, A. Anagnostopoulos, M.-C. Kyrtsonis, K. Zervas, C. Tsatalas, G. Kokkinis, P. Repoussis, A. Symeonidis, S. Delimpasi, E. Katodritou, et al. Primary Treatment of Waldenstrom Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide J. Clin. Oncol., August 1, 2007; 25(22): 3344 - 3349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vijay and M. A. Gertz Waldenstrom macroglobulinemia Blood, June 15, 2007; 109(12): 5096 - 5103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF]
|
|
|
|
|
|
S. P. Treon, M. A. Gertz, M. Dimopoulos, A. Anagnostopoulos, J. Blade, A. R. Branagan, R. Garcia-Sanz, S. Johnson, E. Kimby, V. LeBlond, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia Blood, May 1, 2006; 107(9): 3442 - 3446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Noronha, T. M. Fynan, and T. Duffy Flare in Neuropathy Following Rituximab Therapy for Waldenstrom's Macroglobulinemia J. Clin. Oncol., January 1, 2006; 24(1): e3 - e3. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Dimopoulos, R. A. Kyle, A. Anagnostopoulos, and S. P. Treon Diagnosis and Management of Waldenstrom's Macroglobulinemia J. Clin. Oncol., March 1, 2005; 23(7): 1564 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Treon, C. Emmanouilides, E. Kimby, A. Kelliher, F. Preffer, A. R. Branagan, K. C. Anderson, S. R. Frankel, and On behalf the Waldenstrom's Macroglobulinemia Clin Extended rituximab therapy in Waldenstrom's macroglobulinemia Ann. Onc., January 1, 2005; 16(1): 132 - 138. [Abstract] [Full Text] [PDF]
|
|